BSX

#165
Boston Scientific Corp.
63.79 USD
+1.24%
Sector: Atención Sanitaria
Básica: USD
Divisa de beneficio: USD
Rango diario
63.76
63.99
Rango anual
60.59
109.49
Cambio diario
+1.24%
Variación mensual
-7.79%
Variación en los últimos 6 meses
-33.47%
Cambio anual
-32.70%
Cierres anteriores
63.01
Abrir
63.93
Bid
Ask
Mínimo
63.76
High
63.99
Volumen
2 118
Ver el calendario completo

Financials

Visión general Informes Estadísticas
Trimestre Año
  • Market Capitalization 94.66 B
  • Employee 59 K
  • Founded 1979
  • CEO Michael F. Mahoney
  • Website www.bostonscientific.com
  • Headquarter Delaware, United States
  • FIGI BBG000C0LW92
  • Industry Technology
Ingresos totales
Beneficio neto
Beneficio básico por acción
Deuda total
Flujo de caja libre
Efectivo y equivalentes
Ratio precio/beneficio
49.15
Relación precio/flujo de caja
7.1

Boston Scientific Corporation

Boston Scientific Corporation is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology. The company is known for the development of the Taxus Stent, a drug-eluting stent which is used to open clogged arteries. The company acquired Cameron Health in June 2012 and began to offer a minimally invasive implantable cardioverter-defibrillator called the EMBLEM subcutaneous implantable defibrillator. Over the last 20 years, Boston Scientific has had some high-profile patent infringement cases. It has made extensive payouts, including $1.725 billion to Johnson & Johnson, $85 million to Nevro and $42 million to TissueGen. BSC is headquartered in Marlborough, Massachusetts and incorporated in Delaware.

Noticias